Bonk (BNKK) – Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Bonk (NASDAQ: BNKK) recently:

• 12/15/2025 – Bonk had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Bonk was upgraded by analysts at Wall Street Zen to a “sell” rating.
• 12/8/2025 – Bonk had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Bonk had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Bonk had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Bonk had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Bonk had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/7/2025 – Bonk is now covered by analysts at Weiss Ratings. They set a “sell (d-)” rating on the stock.

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.